Sugi Predict

Sugi Predict / Compounds / SCHEMBL4606123

SCHEMBL4606123

SCHEMBL4606123

CC(C)(C)NC(=O)c1ncccc1CCc1cccc(Cl)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 1/20 0.53
▸ ANO1 Q5XXA6 5/20 0.51
▸ NPC1 O15118 2/20 0.44
▸ GAA P10253 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ BRD4 O60885 1/20 0.42
▸ GRM4 Q14833 1/20 0.41
▸ HDAC3 O15379 1/20 0.41
▸ HDAC1 Q13547 1/20 0.41
▸ HDAC2 Q92769 1/20 0.41
▸ HDAC6 Q9UBN7 1/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ HIF1A Q16665 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14012061 0.87 BACE1 (0.56) BACE1NPC1GAAMEN1RAB9A
SCHEMBL10740600 0.86 ANO1 (0.49) ANO1MEN1KMT2AHDAC6KDM4E
SCHEMBL10571227 0.86 ANO1 (0.51) ANO1NPC1MEN1RAB9AKMT2A
SCHEMBL9829844 0.85 RAB9A (0.47) NPC1MEN1RAB9AKMT2ASMN1; SMN2
SCHEMBL13962869 0.83 BACE1 (0.60) BACE1NPC1GAAMEN1RAB9A
SCHEMBL7656556 0.81 GRM4 (0.55) BACE1NPC1GAAMEN1RAB9A
SCHEMBL6948731 0.81 BACE1 (0.53) BACE1NPC1GAAMEN1RAB9A
SCHEMBL13962883 0.81 BACE1 (0.62) BACE1NPC1GAAMEN1RAB9A
SCHEMBL4452291 0.81 BACE1 (0.62) BACE1NPC1GAAMEN1RAB9A
Hydrochloric Acid SCHEMBL4603331 0.80 BACE1 (0.60) BACE1NPC1GAAMEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113943268-A Preparation method of loratadine key intermediate 万全万特制药（厦门）有限公司 2022-01-18 — — CN claimed
CN-112707886-A Preparation method of loratadine intermediate 北京万全德众医药生物技术有限公司 2021-04-27 — — CN claimed
CN-105566214-B Preparation process of 3- [2- (3-chlorphenyl) ethyl ] -2-picolinic acid 上海医药工业研究院 2020-05-15 — — CN claimed
CN-113943268-A Preparation method of loratadine key intermediate 万全万特制药（厦门）有限公司 2022-01-18 — — CN disclosed
CN-112707886-A Preparation method of loratadine intermediate 北京万全德众医药生物技术有限公司 2021-04-27 — — CN disclosed
CN-105566214-B Preparation process of 3- [2- (3-chlorphenyl) ethyl ] -2-picolinic acid 上海医药工业研究院 2020-05-15 — — CN disclosed
US-8076330-B2 Dipeptidyl peptidase-IV inhibitors AMGEN INC. (US) 2011-12-13 — — US disclosed
US-20110112051-A1 Dipeptidyl Peptidase-IV Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2011-05-12 — — US disclosed
US-20100009961-A1 DIPEPTIDYL PEPTIDASE-IV INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2010-01-14 — — US disclosed
US-20100009961-A1 DIPEPTIDYL PEPTIDASE-IV INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2010-01-14 — — US disclosed
US-7553861-B2 Dipeptidyl peptidase-IV inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-06-30 — — US disclosed
US-4873335-A 3-phenethyl-2-benzene-amides or aza-derivatives thereof SCHERING CORPORATION (US) 1989-10-10 — — US disclosed
EP-0330673-A1 BENZO 5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE SCHERING CORPORATION (US) 1989-09-06 — — EP disclosed
US-4863931-A ANTIALLERGENS SCHERING CORPORATION (US) 1989-09-05 — — US disclosed
US-4826853-A ANTIALLERGENS, ANTIINFLAMMATORY AGENTS SCHERING CORPORATION (US) 1989-05-02 — — US disclosed
EP-0270818-A1 Benzo(5,6)cycloheptapyridines, compositions and method of use SCHERING CORPORATION (US) 1988-06-15 — — EP disclosed
WO-1988003138-A1 BENZO[5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE SCHERING CORPORATION (US) 1988-05-05 — — WO disclosed
US-4731447-A Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof SCHERING CORPORATION (US) 1988-03-15 — — US disclosed
US-4659716-A Antihistaminic 8-(halo)-substituted 6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridines SCHERING CORPORATION (US) 1987-04-21 — — US disclosed
EP-0208855-A1 Process for preparing piperidylidene dihydrodibenzo(a,d)cycloheptenes and aza derivatives thereof, compounds obtained by such process and the use of such compounds for preparing useful pharmaceutical compositions SCHERING CORPORATION (US) 1987-01-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009961-A1 DIPEPTIDYL PEPTIDASE-IV INHIBITORS DPP4, DPP3, DPP7 BACE1 1038/4885ANO1 4236/4885NPC1 1571/4885
US-20110112051-A1 Dipeptidyl Peptidase-IV Inhibitors DPP4, DPP3, DPP7 BACE1 1038/4885ANO1 4236/4885NPC1 1571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.